The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice

Scientific Reports
Daniel F ManvichDavid Weinshenker

Abstract

Clozapine-N-oxide (CNO) has long been the ligand of choice for selectively activating Designer Receptors Exclusively Activated by Designer Drugs (DREADDs). However, recent studies have challenged the long-held assertion that CNO is otherwise pharmacologically inert. The present study aimed to 1) determine whether CNO is reverse-metabolized to its parent compound clozapine in mice (as has recently been reported in rats), and 2) determine whether CNO exerts clozapine-like interoceptive stimulus effects in rats and/or mice. Following administration of 10.0 mg/kg CNO, pharmacokinetic analyses replicated recent reports of back-conversion to clozapine in rats and revealed that this phenomenon also occurs in mice. In rats and mice trained to discriminate 1.25 mg/kg clozapine from vehicle, CNO (1.0-20.0 mg/kg) produced partial substitution for the clozapine stimulus on average, with full substitution being detected in some individual animals of both species at doses frequently used to activate DREADDs. The present demonstration that CNO is converted to clozapine and exerts clozapine-like behavioral effects in both mice and rats further emphasizes the need for appropriate control groups in studies employing DREADDs, and highlights the u...Continue Reading

References

Sep 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R J BaldessariniB M Cohen
Sep 2, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·W H ChangM W Jann
Oct 16, 1999·Fundamental & Clinical Pharmacology·H BunJ Catalin
Feb 24, 2001·Journal of Psychopharmacology·K J AitchisonF J Gonzalez
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Blaine N ArmbrusterBryan L Roth
Oct 28, 2009·Proceedings of the National Academy of Sciences of the United States of America·Jean-Marc GuettierJürgen Wess
Aug 26, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jason P SchroederDavid Weinshenker
Sep 27, 2013·The Journal of Pharmacology and Experimental Therapeutics·Daniel F ManvichDavid Weinshenker
Oct 9, 2014·Annual Review of Pharmacology and Toxicology·Daniel J Urban, Bryan L Roth
May 29, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nathan J MarchantYavin Shaham
Feb 26, 2016·Behavioral Neuroscience·Kyle S SmithStephen V Mahler
Mar 23, 2017·ACS Chemical Neuroscience·Jessica RaperAdriana Galvan
Aug 5, 2017·Science·Juan L GomezMichael Michaelides

❮ Previous
Next ❯

Citations

Sep 19, 2018·ELife·Aleksandra BaduraSamuel S-H Wang
Jun 23, 2019·Journal of Neuroscience Research·Chiara CiriachiMattias Rickhag
Jan 21, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kevin R CoffeyJohn F Neumaier
May 20, 2020·Journal of Neuroscience Research·Kevin UngBenjamin Deneen
Apr 7, 2020·The European Journal of Neuroscience·Mayank AggarwalJeffery R Wickens
Jul 30, 2020·Journal of Neuroscience Research·Kolter B GrigsbyFrank W Booth
Dec 14, 2018·The Journal of Pharmacology and Experimental Therapeutics·Daicia C AllenVerginia C Cuzon Carlson
Dec 18, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Rachel I AndersonHoward C Becker
Dec 19, 2018·Learning & Memory·Jacqueline M BarkerL Judson Chandler
Mar 27, 2019·Molecular Autism·Ishita DasSharmila Banerjee-Basu
Sep 26, 2019·Frontiers in Neuroscience·Elvis Cela, Per Jesper Sjöström
Jul 10, 2020·Brain Structure & Function·Laura DurieuxLucas Lecourtier
Jun 7, 2019·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Kristina HerfertBernd J Pichler
Jan 23, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Puneet K SharmaIlse S Pienaar
Mar 21, 2020·Nature Communications·Sarika PaulTimothy M Brown
Feb 11, 2020·Frontiers in Neuroinformatics·Francesca MandinoJoanes Grandjean
Feb 26, 2019·Scientific Reports·Carie R BoychukBret N Smith
Jun 11, 2019·Frontiers in Physiology·Vena K MartinezRussell S Ray
Apr 9, 2020·Scientific Reports·Jongwook ChoHyoung-Ihl Kim
Jun 10, 2020·The Journal of Clinical Investigation·Ying TanXiao-Bing Gao
May 14, 2020·Molecular Psychiatry·Tina NotterJeremy Hall
Mar 21, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nicholas A Upright, Mark G Baxter
Nov 19, 2019·Frontiers in Behavioral Neuroscience·Sonali S SalviVidita A Vaidya
Oct 29, 2020·Journal of the Experimental Analysis of Behavior·Paul L Soto
Oct 10, 2020·American Journal of Physiology. Heart and Circulatory Physiology·Jhansi Dyavanapalli

❮ Previous
Next ❯

Software Mentioned

GraphPad Prism
DREADDs
GraphPad

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here